AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aumeran, C.
Right arrow Articles by Bonnet, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aumeran, C.
Right arrow Articles by Bonnet, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 2958-2961, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2958-2961.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Effects of Ser130Gly and Asp240Lys Substitutions in Extended-Spectrum ß-Lactamase CTX-M-9

C. Aumeran,1 C. Chanal,1 R. Labia,2 D. Sirot,1 J. Sirot,1 and R. Bonnet1*

Laboratoire de Bactériologie, Faculté de Médecine, 63001 Clermont-Ferrand, Cedex,1 UMR 175, CNRS-MNHN, 29000 Quimper, France2

Received 17 April 2003/ Returned for modification 23 May 2003/ Accepted 4 June 2003


   ABSTRACT
Top
 Abstract
Text
 References
 
In CTX-M-9 extended-spectrum ß-lactamases (ESBLs), an S130G mutation induced a 40- to 650-fold increase in 50% inhibitory concentrations but decreased hydrolytic activity against cefotaxime. A D240K mutation did not modify enzymatic efficiency against ceftazidime. Residue K240 could interact with Q270 and therefore not with ceftazidime, in contrast with what was observed with certain TEM/SHV-type ESBLs.


   TEXT
Top
 Abstract
 Text
References
 
CTX-M extended-spectrum ß-lactamases (ESBLs) are generally characterized by much greater hydrolytic activity against cefotaxime than against ceftazidime (2, 3). Three recently described enzymes, CTX-M-15 (1, 12), CTX-M-16 (6), and CTX-M-19 (19), have greater enzymatic efficiency against ceftazidime. CTX-M-15 and CTX-M-16 harbor an Asp->Gly substitution in position 240. Position 240 is known to play a major role in the activity against ceftazidime of certain TEM/SHV-type ESBLs (10, 13). Nevertheless, positively charged residues (Lys and Arg) are always observed in these ESBLs. Currently, CTX-M enzymes are susceptible to inhibitors of ß-lactamases, whereas TEM/SHV-type enzymes have acquired a high level of resistance to inhibitors, notably through an S130G substitution (4, 16, 18, 20), which is directly implicated in the inhibition process (7, 8).

By analogy with SHV/TEM-type enzymes, we investigated in the present study whether CTX-M-9 enzyme could improve its activity against ceftazidime or acquire resistance to inhibitors by D240K and S130G substitutions, respectively.

The CTX-M-9-encoding plasmid pClRio-7 (6) was used to introduce the mutations into blaCTX-M-9 by site-directed mutagenesis (14) using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). An S130G mutant was constructed by using the primers M9S130G-A (5'-GCCGCGTTGCAGTACGGCGACAATACCGCCATG-3') and M9S130G-B(5'-ATGGCGGTATTGTCGCCTACTGCAACGCGGC3'), whereas a D240K mutant was constructed by using the primers M9D240K-A (5'-GATAAGACCGGCAGCGGCAAGTACGGCACCACCAATG-3') and M9D240K-B (5'-CATTGTGGTGCCGTACTTGCCGCTGCCGTCTTATC-3') (the mutated codons are underlined). All the mutant genes were sequenced on both strands by the dideoxy chain termination procedure of Sanger et al. (21) as previously reported (5). The MICs of ß-lactams alone or in combination with ß-lactamase inhibitors were determined by a dilution method in agar as previously reported (6). Table 1 lists the MICs of ß-lactams for Escherichia coli DH5{alpha} strains producing CTX-M-9 and the S130G and D240K mutants.


View this table:
[in this window]
[in a new window]
  		TABLE 1. ß-Lactam MICs for E. coli DH5{alpha} producing CTX-M-9, the S130G mutant, and the D240K mutant

 
High levels of resistance were observed for amoxicillin, ticarcillin, and cephalothin (MICs, 64 to >2,048 µg/ml) for the three ß-lactamases. Combination with clavulanate did not restore the activity of amoxicillin and ticarcillin for S130G mutant-producing E. coli, whereas activity was restored with the strain producing the D240K mutant and CTX-M-9 (MICs, 256 to 512 µg/ml versus 8 to 32 µg/ml). The MICs of cefotaxime (0.25 versus 8 µg/ml), ceftazidime (0.12 versus 1 µg/ml), and aztreonam (0.12 versus 2 to 4 µg/ml) were lower for S130G mutant-producing E. coli than for D240K mutant-producing and CTX-M-9-producing E. coli. Overall, the S130G mutant induced a resistance phenotype similar to that conferred by inhibitor-resistant or overexpressed TEM-type penicillinase (8), whereas the resistance phenotype conferred by the D240K mutant was similar to that of parental enzyme CTX-M-9.

The two mutant enzymes were extracted from recombinant E. coli DH5{alpha} by sonication and purified by ion exchange and gel filtration as previously described (6). The kinetic constants of purified enzymes (purity rates >= 96%) were obtained by a computerized microacidimetric method as previously described (15). The concentrations of inhibitors required to inhibit enzyme activity by 50% (IC50s) were determined as previously reported (5).

Inhibition profiles of S130G, D240K, and CTX-M-9 enzymes are shown in Table 2. Those of the latter two were similar, whereas IC50s of the S130G mutant were 40-fold (sulbactam) to 650-fold (tazobactam) higher than those of CTX-M-9.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Inhibition profiles of S130G, D240K, and CTX-M-9 enzymes

 
The kinetic constants of the two mutants and of the parental enzyme CTX-M-9 are listed in Table 3. Compared to CTX-M-9, the S130G mutant showed similar Km values but greatly decreased hydrolytic activity (kcat), particularly on cephalosporins (cephalothin, 3 versus 3,000 s-1; cefotaxime, 0.5 versus 450 s-1). S130G substitution therefore induced resistance to ß-lactam inhibitors but altered the extended-spectrum activity, as previously observed in the SHV/TEM-type complex mutant CMT-3 (18, 20, 23).


View this table:
[in this window]
[in a new window]
  		TABLE 3. Kinetic constants of S130G, D240K, and CTX-M-9 enzymes

 
kcat values for the D240K mutant were weakly increased for penicillin G, cefotaxime, and ceftazidime and similar to those of CTX-M-9 for amoxicillin, ticarcillin, piperacillin and aztreonam. Km values were weakly increased for all ß-lactams. The enzymatic efficiency (kcat/Km) of the D240K mutant was only weakly reduced for cefotaxime (1.5 versus 4 s-1 µM-1) and not significantly increased for ceftazidime (0.005 versus 0.003 s-1 µM-1) in contrast with that observed with CTX-M-16 (a D240G mutant of CTX-M-9) (6) and K240-harboring SHV/TEM-type ESBLs (10, 13).

To investigate the role of residue 240, the structures of CTX-M-9, CTX-M-16, and the D240K mutant were modeled on the basis of the crystallographic structure of the CTX-M enzyme Toho-1 (11). The mutations were introduced as part of an automated procedure using Hyperchem v6.3 software (Hypercube Inc., Gainesville, Fla.). The residues, the catalytic water molecule, and the water molecules of the Toho-1 crystal were minimized using the Amber96 parameters (9) and a distance-dependent dielectric constant by conjugate gradient until the root mean square gradient was <0.1 kcal/mol. The major differences observed between the models obtained and TEM-1 crystallographic structure (17) are shown in Fig. 1.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 1. Structures of CTX-M-9 (A), the D240K mutant (B), and CTX-M-16 (C) obtained by molecular modeling and the crystallographic structure of TEM-1 (D) (17). Two black dots indicate the positions of water molecules: W1, the catalytic water molecule maintained by the lateral chains of residues 166, 170, and 70, and W2, the water molecule of oxyanionic hole formed by the main chains of residues 70 and 237. The hydrogen bonds between residues 170, 240, and 270 are indicated by dashed lines.

 
In the CTX-M enzymes, the loop connecting the ß5 strand and the H11 helix exhibited two additional residues and was oriented towards the C-terminal extremity of the ß3 strand, unlike that in the TEM-type enzyme (Fig. 1D). In the CTX-M-9 and D240K models, residue Asn-270 established a hydrogen bond with D240 and K240 side chains, respectively (Fig. 1A and B), while this hydrogen bond is absent in the CTX-M-16 model and SHV/TEM-type enzymes (10, 13). In the crystal structure of Toho-1 acyl enzymes (22), the interaction between residues 270 and 240 is mediated by a water molecule. However, the calculated energy from a structure harboring a binding mediated by a water molecule was higher than that obtained from the model harboring a direct interaction of residues 270 and 240. This interaction may be involved in the positioning of ß3-strand residues during the catalytic process and could therefore explain the similarities of kinetic constants between CTX-M-9 and D240K, as well as the differences observed with those of CTX-M-16 (6). Molecular modeling suggests that K240 of SHV/TEM-type ESBLs increases enzymatic efficiency against ceftazidime by establishing a hydrogen bond with ceftazidime (10, 13). In CTX-M, this interaction could be altered by the interaction between residues 240 and 270, the latter of which orients the K240 side chain away from the active site of the enzyme.

In conclusion, CTX-M-9 behaved like SHV/TEM-type ß-lactamases with regard to an S130G substitution but not the substitution in position 240, probably because of a slight structural difference in the loop connecting the ß5 strand and the H11 helix.


   ACKNOWLEDGMENTS
 
We thank Rolande Perroux, Marlene Jan, and Dominique Rubio for technical assistance.

This work was supported in part by a grant from the Ministère de l'Education Nationale de la Recherche et de la Technologie.


   FOOTNOTES
 
* Corresponding author. Mailing address: Faculté de Médecine, Service de Bactériologie-Virologie, 28, Place Henri Dunant, 63 001 Clermont-Ferrand Cedex, France. Phone: 33 (0)4 73 17 81 50. Fax: 33 (0)4 73 27 74 94. E-mail: richard.bonnet{at}u-clermont1.fr. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Baraniak, A., J. Fiett, W. Hryniewicz, P. Nordmann, and M. Gniadkowski. 2002. Ceftazidime-hydrolysing CTX-M-15 extended-spectrum ß-lactamase (ESBL) in Poland. J. Antimicrob. Chemother. 50:393-396.[Abstract/Free Full Text]
  2. Barthélémy, M., J. Péduzzi, H. Bernard, C. Tancrède, and R. Labia. 1992. Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum ß-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca. Biochim. Biophys. Acta 1122:15-22.[CrossRef][Medline]
  3. Bauernfeind, A., J. M. Casellas, M. Goldberg, M. Holley, R. Jungwirth, P. Mangold, T. Rohnisch, S. Schweighart, and R. Wilhelm. 1992. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection 20:158-163.[CrossRef][Medline]
  4. Bermudes, H., F. Jude, E. B. Chaïbi, C. Arpin, C. Bebear, R. Labia, and C. Quentin. 1999. Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived ß-lactamase in a clinical isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 43:1657-1661.[Abstract/Free Full Text]
  5. Bonnet, R., J. L. M. Sampaio, R. Labia, C. De Champs, D. Sirot, C. Chanal, and J. Sirot. 2000. A novel CTX-M ß-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob. Agents Chemother. 44:1936-1942.[Abstract/Free Full Text]
  6. Bonnet, R., C. Dutour, J.-M. Sampaio, C. Chanal, D. Sirot, R. Labia, C. De Champs, and J. Sirot. 2001. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240->Gly. Antimicrob. Agents Chemother. 45:2269-2275.[Abstract/Free Full Text]
  7. Brown, R., R. Aplin, and C. Schofield. 1996. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35:12421-12432.[CrossRef][Medline]
  8. Chaïbi, E. B., D. Sirot, G. Paul, and R. Labia. 1999. Inhibitor-resistant TEM ß-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43:447-458.[Abstract/Free Full Text]
  9. Cornell, W., P. Cieplak, C. Bayly, I. Gould, K. Merz, D. Ferguson, D. Spellmeyer, T. Fox, J. Caldwell, and P. Kollman. 1995. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:5179-5197.[CrossRef]
  10. Huletsky, A., J. Knox, and R. Levesque. 1993. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type ß-lactamases probed by site-directed mutagenesis and three-dimensional modeling. J. Biol. Chem. 268:3690-3697.[Abstract/Free Full Text]
  11. Ibuka, A., A. Taguchi, M. Ishiguro, S. Fushinobu, Y. Ishii, S. Kamitori, K. Okuyama, K. Yamaguchi, M. Konno, and H. Matsuzawa. 1999. Crystal structure of the E166A mutant of extended-spectrum ß-lactamase Toho-1 at 1.8 A resolution. J. Mol. Biol. 285:2079-2087.[CrossRef][Medline]
  12. Karim, A., L. Poirel, S. Nagarajan, and P. Nordmann. 2001. Plasmid-mediated extended-spectrum ß-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol. Lett. 201:237-241.[Medline]
  13. Knox. J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type ß-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601.[Medline]
  14. Künkel, T. 1985. Rapid and efficient site-specific mutagenesis without phenotypic and selection. Proc. Natl. Acad. Sci. USA 82:488.[Abstract/Free Full Text]
  15. Labia, R., J. Andrillon, and F. Le Goffic. 1973. Computerized microacidimetric determination of ß-lactamase Michaelis-Menten constants. FEBS Lett. 33:42-44.[CrossRef][Medline]
  16. Leflon-Guibout, V., V. Speldooren, B. Heym, and M.-H. Nicolas-Chanoine. 2000. Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of blaTEM genes. Antimicrob. Agents Chemother. 44:2709-2714.[Abstract/Free Full Text]
  17. Minasov, G., X. Wang, and B. Shoichet. 2002. An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J. Am. Chem. Soc. 124:5333-5340.[CrossRef][Medline]
  18. Neuwirth, C., S. Madec, E. Siebor, A. Pechinot, J.-M. Duez, M. Pruneaux, M. Fouchereau-Peron, A. Kazmierczak, and R. Labia. 2001. TEM-89 ß-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob. Agents Chemother. 45:3591-3594.[Abstract/Free Full Text]
  19. Poirel, L., T. Naas, I. Le Thomas, A. Karim, E. Bingen, and P. Nordmann. 2001. CTX-M-type extended-spectrum ß-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob. Agents Chemother. 45:3355-3361.[Abstract/Free Full Text]
  20. Prinarakis, E. E., V. Miriagou, E. Tzelepi, M. Gazouli, and L. S. Tzouvelekis. 1997. Emergence of an inhibitor-resistant b-lactamase (SVH-10) derived from SHV-5 variant. Antimicrob. Agents Chemother. 41:838-840.[Abstract]
  21. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.[Abstract/Free Full Text]
  22. Shimamura, T., A. Ibuka, S. Fushinobu, T. Wakagi, M. Ishiguro, Y. Ishii, and H. Matsuzawa. 2002. Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin and benzylpenicillin. J. Biol. Chem. 277:46601-46608.[Abstract/Free Full Text]
  23. Sirot, D., R. Labia, P. Pouedras, C. Chanal-Claris, C. Cerceau, and J. Sirot. 1998. Inhibitor-resistant oxy-2-derived ß-lactamase produced by Klebsiella oxytoca. Antimicrob. Agents Chemother. 42:2184-2187.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, September 2003, p. 2958-2961, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2958-2961.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aumeran, C.
Right arrow Articles by Bonnet, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aumeran, C.
Right arrow Articles by Bonnet, R.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS